MT 1980
Alternative Names: MT-1980Latest Information Update: 02 Feb 2026
At a glance
- Originator Monument Therapeutics
- Class Anti-inflammatories; Antipsychotics; Nootropics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Schizophrenia
- Discontinued Cognition disorders; Neurological disorders
Most Recent Events
- 02 Feb 2026 Discontinued - Phase-I for Cognition disorders (In volunteers) in Netherlands (PO) before February 2026 (Monument Therapeutics pipeline, February 2026)
- 02 Feb 2026 Discontinued for Neurological disorders in United Kingdom (PO) before February 2026 (Monument Therapeutics pipeline, February 2026)
- 02 Feb 2026 Phase-I clinical trials in Schizophrenia (PO) before February 2026 (Monument Therapeutics pipeline, February 2026)